Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Flipper,
OK, thanks! and "Stephen W" is Stephen Western!
I found this testimony of the wife of a German patient. Pay particular attention to what she tells in the end. What do you call someone who can not keep secrets?
I'll give you the German version first and then Google Translate.
Dec 1, 2015
Sentiment,
We know from the SNO data that a total of 28.2% of all 331 patients, or 93, made it past 36 months.
I'm pretty sure it's 94 at this time. See OS curve 2018.
91 patients made it past 36 months and you see 3 censors between 35 and 36 months.
Of 2 of these 3 patients there was recently news available on the web.(good news)
Survival at 3 years for the unmethylated = 162 patients is 14.3%.
14.3% of 162 =23.16.
23 unmethylated patients made it past 36 months and you see 2 LTFU unmethylated censors around 9 months on the last 2018 OS unmethylated curve.
https://pbs.twimg.com/media/DsOGDz_W0AAeYpL.jpg
We know from our analysis (and your great work) that 8 out of 23 unmethylated patients come from the first 223 patients.
15 of these 23 unmethylated patients come from the last group of 108.
It is also my guess that NO CONTROL meth- patients lived to 36 months.
So in that case: 223 – 38 unknown= 185 patients (methylated and unmethylated)(placebo and treatment).
2/3 treatment = 123 patients
55.4% of 123 unmethylated= 68 unmethylated treatment patients.
8 of these 68 made it to 36 months = 11.7% (if you believe that all 8 patients are from the treatment group= DCVAX-L from the start.)
In that last group of 108 patients we have 46 unmethylated patients (83 treatment X 55.4% = 46 unmethylated)
15 of these last 46 unmethylated patients made it to 36 months =32.6% (if you believe that all 15 patients are from the treatment group= DCVAX-L from the start.)
32.6% against 11.7%
I think this is additional evidence that a change took place when the Germans came on board. In the meantime I found more evidence pointing in that direction (data, German comment, reaction Germans on the publication 2017, story Australian GBM patient etc.)
Read this:
meirluc,
Approximately 60 to 62 patients from the last group of 108 lived at least 24 months after their surgery. See publication 2017 and the data 2018.
Marzan,
Dr Liau PET scan method was for differentiating tumor progression from pseudoprogression.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617282/
reg2015,
Erik Ramos - Special Projects, Northwest Biotherapeutics
Erik Ramos's Email
Manager @ Northwest Biotherapeutics (Past)
Location Darien, Connecticut
Work Strategic Planning Analyst @ Booz Allen Hamilton
Sr. Financial Analyst @ Pepsi Bottling Group
Education 2012 2013 Master of Business Administration (MBA) @ INSEAD
2001 2005 A.B. @ Princeton University
Minority Introduction to Engineering in Entrepreneurship & Science (MITEES) @ M.I.T.
https://rocketreach.co/erik-ramos-email_4961672
• Erik Ramos Special Projects, Northwest Biotherapeutics Inc
Eric R.?????
https://www.linkedin.com/in/erik-r-4405777/
Erik R.
Manager at Northwest Biotherapeutics
Darien, Connecticut
Intrests:
Chinese MBA Club
Standard group
1,453 members
https://www.linkedin.com/groups/4820333/
About this group
The Chinese MBA Club (CMC) is an organization for all MBAs of Chinese origin and MBAs interested in China to share business information and opportunities related to China. With the booming Chinese market and quick expansion of Chinese firms globally, many business opportunities are emerging. CMC aims at supporting MBA talent, companies, governments, and organizations in developing and growing those opportunities. Vision: The Chinese MBA Club wants to become the most influential Chinese MBA organization in the world. Mission: The Chinese MBA Club aims at providing a platform for all MBAs, companies, governments and organizations that have a Chinese background or are interested in China, to exchange business information and create new opportunities for cooperation. It will assist MBA students in terms of academic-related issues, and support MBAs in personal and career development, and in bridging the gap between industry needs and MBA talent. Associates of the club: • All MBAs of Chinese origin • All MBAs with interest in China or Chinese business/firms.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=115361541
Major UK Parliamentary report reveals the very high ongoing costs of brain tumours
A UK Parliamentary committee established in 2005, called the All-Party Parliamentary Group on Brain Tumours (APPGBT), has published a wide-ranging report about the economic and social impacts of brain tumours borne by patients, families and wider society. The report details these financial costs, many of which are 'invisible', stating that the average household affected by a brain tumour will be financially worse off by £14,783 (19,000 USD) per year, versus £6,840 for all cancers.The economic costs of brain tumours among working age people are ranked third highest among the common cancers, behind lung and breast cancer. The report gives recommendations to reduce financial burden to brain tumour patients and their families, as well as identifying ways to improve patient experience.
Brain Tumours A cost too much to bear?
Report of the All-Party Parliamentary Group on Brain Tumours
Inquiry into the economic and social impacts of brain tumours
This is not an official publication of the House of Commons or the House of Lords. It has not been approved by either House or its committees. All-Party Parliamentary Groups are informal groups of Members of both Houses with a common interest in particular issues. The views expressed in this report are those of the group. This report was compiled by the Brain Tumour Research charity which provides the Secretariat to the All-Party Parliamentary Group on Brain Tumours.
flipper44,
Thanks for that article about AI.
artificial intelligence (AI)
Here is another article:Let’s Activate Intelligence.
https://www.huawei.com/us/about-huawei/publications/winwin-magazine/31/activate-intelligence
john1045,
good find! Thanks!! I like the title!!!
IN THE NEWS
Campbell Lecturer Details New Directions in Brain Cancer Treatment
December 20, 2018 | Goodman Campbell | Brain Health, Events
sharpie510,
If you search, you can find the story of these three patients on the web.
After reading their story, I strongly suspect that the three patients who got second resection were all treatment from the start. One of these patients belongs to the last group enrolled in the trial.
All three patients died a few months after second surgery.
Huawei Technologies Research & Development (UK) Limited
Location info - Huawei Technologies Research and Development (UK) Limited
Unit 302, Cambridge Science Park
Milton Road
Cambridge
Cambridgeshire
CB4 0WG
United Kingdom
Location info - Huawei Science Park
Unit 101 Science Park
Milton Road
Cambridge
Cambridgeshire
CB4 0FY
United Kingdom
https://www.cambridgewireless.co.uk/members/huawei-technologies-research-and-development/
SNO-CAP 2018: RECAPPING THE ANNUAL MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY
By Tom Halkin | Published December 17, 2018
GOV.UK
Department for Business, Energy & Industrial Strategy.
Office for Life Sciences.
Policy paper
Life Sciences Sector Deal 2, 2018
Updated 5 December 2018
https://www.gov.uk/government/publications/life-sciences-sector-deal/life-sciences-sector-deal-2-2018
Longfellow95,
I found this:
First published March 8, 2018
“Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial”
Bruno Francois,1,2,3 Robin Jeannet,2 Thomas Daix,1,2 Andrew H. Walton,4 Matthew S. Shotwell,5 Jacqueline Unsinger,4 Guillaume Monneret,6,7 Thomas Rimmelé,7,8 Teresa Blood,4 Michel Morre,9 Anne Gregoire,9 Gail A. Mayo,10 Jane Blood,4 Scott K. Durum,11 Edward R. Sherwood,10,12 and Richard S. Hotchkiss4,13,14
FUNDING. Revimmune, NIH National Institute of General Medical Sciences GM44118.
Conflict of interest: M. Morre and A. Gregoire are Revimmune employees.
https://insight.jci.org/articles/view/98960#FN
Anne Grégoire
Director Process Development
Company Name Revimmune
Dates Employed Jun 2014 – Present
Employment Duration 4 yrs 7 mos
Location Paris Area, France
Interests- Following Companies: Toucan Capital, Northwest Biotherapeutics, Cognate Bioservices, ……
https://www.linkedin.com/in/anne-grégoire-86639b57/
Michel MORRE
Chief Science Officer chez REVIMMUNE
https://www.linkedin.com/in/michel-morre-7b6556153/?originalSubdomain=be
Interleukin 7 - Revimmune SAS
Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007
Latest Information Update: 19 Sep 2018
https://adisinsight.springer.com/drugs/800020133
Longfellow95,
I found information about the “Entreprise Revimmune SAS à Paris”.
The information is in French but I think you can handle that….
Nom : Revlmmune SAS
Date de démarrage d'activité : 17/06/2014
Activité : recherche et développement biopharmaceutiques, incluant le développement de nouvelles molécules, la conduite d'essais cliniques et la commercialisation de ces nouveaux produits, médicaments ou molécules…
Président : Revlmmune, Inc., société du Delaware (Delaware Corporation) de droit américain, sise 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814, Etats-Unis, authentification n o 1401874, représentée par Mme Linda Fairing Powers demeurant 9306 Kendale Road, Potomac, MD 20854 Etats-Unis.
Directeur Général : M. James Kelly Ganjei demeurant 10609 River Oaks Lane, Potomac, MD 20854 Etats-Unis.
http://entreprises.lefigaro.fr/revimmune-sas-75/entreprise-803071729
Flipper44,
This is from a GBM patient blog:
e-mail:
Doc logic,
Is this a piece of the puzzle?:
Longfellow95,
Philippe Pire
Chief Financial Officer
Results-driven CEO/CFO. 25+ years' business/operational finance experience. Develop global financial strategy, raise capital, manage investments, create sustainable value, implement efficiencies and internal controls, M&A integration, problem solve and IR. M&A experience includes acquisitions and divestitures.
Armed with quantitative and analytical skills, I am well-equipped to address pressing challenges and capitalize on opportunities. Managed teams of 100+ in economically volatile environments, Accustomed to solving multiple issues creatively and under extreme pressure. I actively anticipate when to implement changes in direction, prioritizing and delegating tasks, and motivating others to achieve targeted objectives in a timely and efficient manner.
Key strengths include:
FINANCE
• Lead continuous evaluation of short/long-term strategic financial objectives
• Optimize management of capital sources and their uses
• M&A
• Investor Relations (manage relationships with financial markets; lenders; investors; etc.)
• Timely, accurate analysis of budgets, financial trends and forecasts
• Audit, budget and financial forecasting
• Strategically enhance financial performance and business opportunities
• Seek and negotiate capital raising transactions
• Ensure effective internal controls, compliance with GAAP and applicable regs governing financial and tax reporting
MANAGEMENT/LEADERSHIP
• Develop strategic plan
• Hire, motivate and direct teams of men and women
• Create new organizations and deploy work force
BUSINESS DEVELOPMENT
• Design strategies to achieve, sustain and recapture market leadership and growth
• Expand geographic footprint/wholesale and retail franchise operations in appropriate global markets
• Launch new product lines
• Increase manufacturing capabilities
• Improve brand name recognition
COMMUNICATION
• Liaise with media in connection with PR strategy
Experience
Company Name Cognate BioServices
Total Duration 3 yrs 11 mos
Title Special Advisor, Strategy and Corporate Finance
Dates Employed Mar 2018 – Present
Employment Duration 10 mos
Location Greater New York City Area
I act as special advisor to the senior executive management team, drawing on deep expertise in strategy and corporate finance to drive value creation, growth and optimal allocation of resources.
https://www.linkedin.com/in/philippe-pire-2b700833/
Longfellow95,
Last year there was only a contact person.
Contact: Tina Crombie Head of Business Operations tcrombie@adventbio.uk
https://ct.catapult.org.uk/sites/default/files/publication/GMP%20Manufacturing%20Report%202017%2030_12_17%20FINAL.pdf
This year same contact person Tina Crombie but for the first time a Chief Operations Officer= Philippe Pire.
Tina Crombie Head of Business Operations tcrombie@adventbio.uk 0203 627 9960/ 07905 658843
Philippe Pire Chief Operations Officer ppire@adventbio.uk 0203 627 9960
https://ct.catapult.org.uk/sites/default/files/publication/2018%20GMP%20Manufacturing%20Report_FINAL.pdf
I agree,
Ceci est où l'intrigue se corse.
Longfellow95,
Thank you for the update! Great find!
Longfellow95,
I agree, they are all in on getting this done first time round.
The last clinical results are particularly strong. IMO
Longfellow95,
17 MAY 2012 Northwest Bio Provides Update On DCVax® -L Brain Cancer Trial.
Gerno Schmiedeknecht, Head of Main Department GMP Cell and Gene Therapy at Fraunhofer Institute for Cell Therapy and Immunology IZI, “likes” the 2018 SNO data.
https://www.linkedin.com/in/gerno-schmiedeknecht-9a289850/detail/recent-activity/